Serum Institute seeks Rs 100 cr in damages from trial subject

As questions mount on Oxford-AstraZeneca vaccine trials in India after a 40-year-old participant fell sick and sought damages of Rs 5 crore, Serum Institute of India (SII) has said the allegations in his legal notice are “malicious and misconceived”, and the firm will ask for damages in excess of Rs 100 crore for them. The SII Chief Executive on Saturday indicated the company would apply to the regulator in two weeks for an emergency use authorisation (EUA) of the vaccine. The volunteer fell sick 10 days after he was given a shot on October 1 in the clinical trial of Co.....

Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel